



## Claims


1. A compound according to the formula:




where X is selected from the group consisting of  $R^a$ ,  $R^b$ ,  $R^c$ ,  $R^d$ ,  $R^e$ ,  $R^f$  and  $R^g$ ;




where  $R^1$  is an isobutylene group;




where  $R^2$  and  $R^3$  are independently a  $C_1$ - $C_5$  linear or branched-chain alkyl or alkene group;





where  $R^2$  is the same as above;




where  $R^2$  is the same as above and wherein said AR group is a phenyl, naphthyl, para or ortho substituted biphenyl group;

$R^e$  is , where  $R^4$  is a  $C_1$ - $C_5$  linear or branch-chained alkyl or alkene group, allyl or homoallyl group and  $R^5$  is a  $C_1$ - $C_5$  linear or branch-chained alkyl or alkene group;

$R^f$  is , where  $R^2$  and  $R^3$  are the same as is set forth above,

$R^g$  is  where  $R^2$  is the same as is set forth above;

Z is a  $C_1$ - $C_{12}$  alkyl or alkylene group, or a group according to the structure




wherein each of said groups may be optionally substituted with one or more halogen groups;


R is H or a  $C_1$ - $C_{18}$  alkyl group; and

pharmaceutically acceptable salts, anomers, solvates and polymorphs, thereof.

2. The compound according to claim 1 wherein said formula is:



3. The compound according to claim 2 wherein X is R<sup>d</sup>, R<sup>e</sup> or R<sup>f</sup>.
4. The compound according to any of claims 1-3 wherein R<sup>2</sup> or R<sup>4</sup> is isobutenyl.
5. The compound according to any of claims 1-4 where X is R<sup>a</sup>.
6. The compound according to any of claims 1-4 where X is R<sup>b</sup>.
7. The compound according to any of claims 1-4 where X is R<sup>c</sup>.
8. The compound according to any of claims 1-4 where X is R<sup>d</sup>.
9. The compound according to any of claims 1-4 where X is R<sup>e</sup>.
10. The compound according to any of claims 1-4 where X is R<sup>f</sup>.
11. The compound according to any of claims 1-4 where X is R<sup>g</sup>.
12. The compound according to any of claims 1-11 where R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> or R<sup>5</sup> is an isobutenyl group.
13. The compound according to any of claims 1-12 wherein Z is CH<sub>3</sub>.
14. The compound according to any of claims 1-12 wherein Z is a group according to the structure:




wherein each of said groups is optionally substituted with one or two fluorine groups.

15. The compound according to any of claims 1-12 and 14 wherein Z is a biphenyl group.


16. The compound according to any of claims 1-15 wherein R is H.

17. A pharmaceutically acceptable salt of the compound according to claim 14.

18. The compound according to any of claims 1, 2, 3, 4 and 8 wherein AR is



19. The compound according to claim 18 wherein AR is



20. The compound according to any of claims 1-14 and 17-19 wherein R is a C<sub>1</sub>-C<sub>18</sub> alkyl group.

21. The compound according to any of claims 1-20 wherein R<sup>2</sup> or R<sup>4</sup> is isobutenyl.

22. A pharmaceutical composition comprising an effective amount of a compound according to any of claims 1-21, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

23. A method for treating neoplasia in a patient in need thereof comprising administering to said patient an effective amount of a compound according to any of claims 1-22.

24. The method according to claim 23 wherein said neoplasia is a tumor.

25. The method according to claim 24 wherein said tumor is cancerous.

25. The method according to claim 23 or 24 wherein said neoplasia is a cancer of the stomach, colon, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, bladder, renal, brain/cns, head and neck, throat, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, melanoma, acute lymphocytic leukemia, acute myelogenous leukemia, Ewings Sarcoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, Wilms Tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx, oesophagus, larynx, melanoma or kidney.

26. A method for treating a patient in need thereof for a disease or condition selected from the group consisting of hyperproliferative cell growth, restenosis following cardiovascular surgery, hyperplasia and chronic inflammatory diseases comprising administering to said patient suffering from said disease an effective amount of a compound according to any of claims 1-21.

27. The method according to claim 26 wherein said hyperproliferative cell growth disease or condition is hyperkeratosis, keratoderma, lichen, planus, psoriasis, warts or blisters.

28. The method according to claim 27 wherein said hyperkeratosis is ichthyosis.

29. The method according to claim 26 or 27 wherein said hyperproliferative cell growth disease or condition is psoriasis.

30. The method according to claim 27 wherein said warts are genital warts.

31. The method according to claim 26 wherein said hyperplasia is cystic hyperplasia, nodular hyperplasia of the prostate or renal hyperplasia.

32. The method according to claim 31 wherein said cystic hyperplasia is cystic hyperplasia of the breast.

33. A method for treating chronic inflammatory disease comprising administering to a patient in need of therapy an effective amount of a compound according any of claims 1-21.
34. The method according to claim 33 wherein said chronic inflammatory disease is rheumatoid arthritis or osteoarthritis.
35. A method of inhibiting isoprenylcysteine methyltransferase enzyme comprising exposing said enzyme to an effective amount of a compound according to any of claims 1-21.
36. A method of inhibiting isoprenyl cysteine methyltransferase enzyme in a patient in order to treat a disease or condition modulated by said enzyme comprising administering to said patient an effective amount of a compound according to any of claims 1-21.
37. Use of a compound according to any of claims 1-21 for the manufacture of a medicament for the treatment of cancer.
38. Use of a compound according to any of claims 1-21 for the manufacture of a medicament for the treatment of a disease or condition selected from the group consisting of hyperproliferative cell growth, restenosis following cardiovascular surgery, hyperplasia and chronic inflammatory diseases.